DEA Denies 2 Cannabis Petitions

It is not yet official but will be tomorrow when the DEA publishes in the Federal Register that they are denying Re-scheduling petitions by Mr. Krumm and also Ms. Raimondo and Mr. Inslee, The Honorable Lincoln D. Chafee and The Honorable Christine O. Gregoire. Here are the notices to be published 2016-17960 and 2016-17954

In Nov of 2011 Raimondo & Inslee filed a petition with the DEA, in July of 2016 Mr Krumm filed a similar petition.  The petitions asked the DEA to once again consider re-scheduling Cannabis into another schedule of the CSA.  “and “related items” removed from Schedule I of the CSA and rescheduled as medical cannabis in Schedule II” and also “Removed from schedule I of the CSA and rescheduled in any schedule other than schedule I of the CSA.”

In it’s final response the DEA states  “Based on the HHS evaluation and all other relevant data, the DEA has concluded that there is no substantial evidence that marijuana should be removed from Schedule I. A document prepared by the DEA addressing these materials in detail also is enclosed. In short, marijuana continues to meet the criteria for Schedule I control under the CSA ”

Adding “Based on the established five-part test for making such determination, marijuana has no “currently accepted medical use” because: As detailed in the HHS evaluation, the drug’s chemistry is not known and reproducible; there are no adequate safety studies; there are no adequate and well-controlled studies proving efficacy; the drug is not accepted by qualified experts; and the scientific evidence is not widely available.”

Further adding “At present, there are no marijuana products approved by the U.S. Food and Drug Administration (FDA), nor is marijuana under a New Drug Application (NDA) evaluation at the FDA for any indication. The HHS evaluation states that marijuana does not have a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. At this time, the known risks of marijuana use have not been shown to be outweighed by specific benefits in well-controlled clinical trials that scientifically evaluate safety and efficacy.”

Finally stating once again that ” in view of United States obligations under international drug control treaties, marijuana cannot be placed in a schedule less restrictive than schedule II.”